

Supplementary Table S1. Overall survival outcomes of metastatic melanoma patients (diagnosed between 2015–2018) by line of therapy stratified by disease type.

Variable	Median Survival (95% CI)	1 Year Survival (95% CI)	2 Year Survival (95% CI)
1L Systemic therapy			
De novo	15.29 (8.84–NA)	0.525 (0.424–0.651)	0.445 (0.343–0.577)
Recurrent	25.22 (20.58–38.53)	0.707 (0.645–0.776)	0.522 (0.451–0.604)
2L Systemic therapy			
De novo	10.62 (4.41–NA)	0.466 (0.298–0.728)	0.266 (0.122–0.581)
Recurrent	10.16 (5.95–16.37)	0.465 (0.352–0.614)	0.263–0.163–0.425)

Supplementary Table S2. Cancer-specific survival outcomes of metastatic melanoma patients (diagnosed between 2015–2018) by treatment type and line of therapy.

Variable	Median Survival (95% CI)	1 Year Survival (95% CI)	2 Year Survival (95% CI)
1L Systemic therapy	28.50 (22.22–NA)	0.689 (0.634–0.749)	0.547 (0.486–0.616)
Ipilimumab/Ipilimumab + Nivolumab	NA (NA–NA)	0.754 (0.654–0.871)	0.666 (0.551–0.804)
PD-1	38.96 (22.22–NA)	0.764 (0.689–0.848)	0.590 (0.498–0.698)
Targeted Therapy	15.29 (9.93–25.22)	0.536 (0.437–0.658)	0.396 (0.299–0.524)
2L Systemic therapy	10.62 (7.86–18.94)	0.499 (0.398–0.625)	0.313 (0.215–0.457)
Ipilimumab/Ipilimumab + Nivolumab	8.81 (3.78–NA)	0.429 (0.241–0.762)	0.286 (0.127–0.641)
PD-1	12.07 (4.90–NA)	0.507 (0.361–0.713)	0.245 (0.119–0.502)
Targeted Therapy	19.46 (8.32–NA)	0.564 (0.403–0.789)	0.452 (0.286–0.715)
3L Systemic therapy	11.24 (5.65–NA)	0.473 (0.295–0.759)	0.249 (0.101–0.609)
PD-1	12.76 (6.48–NA)	0.533 (0.280–1.000)	0.400 (0.170–0.943)
Targeted Therapy	5.65 (3.75–NA)	0.360 (0.150–0.865)	NA